Clearmind Medicine (CMND) Common Equity (2021 - 2026)
Clearmind Medicine (CMND) posted quarterly Common Equity of $11.5 million for Q2 2026, up 399.28% year-over-year from $2.3 million in Q2 2025, and up 39.48% quarter-over-quarter from $8.2 million in Q1 2026.
Clearmind Medicine (CMND) Common Equity (2021 - 2026) Analysis & Trends
Clearmind Medicine's Common Equity history runs 6 years deep, the most recent figure standing at $11.5 million for Q2 2026.
- In Q2 2026, Common Equity rose 399.28% year-over-year to $11.5 million; the TTM figure through Apr 2026 stood at $11.5 million (up 399.28% YoY), while the FY2025 annual figure was $1.2 million, down 61.62% from the prior year.
- Common Equity for Q2 2026 stood at $11.5 million, up from $8.2 million in the prior quarter.
- The five-year high for Common Equity was $11.5 million in Q2 2026, with the low at -$1.1 million in Q4 2022.
- The 5-year median for Common Equity is $3.0 million (2024), against an average of $3.5 million.
- The sharpest annual moves came in 2022 and 2026: Common Equity slumped 129.76% in 2022, then jumped 399.28% in 2026.
- Clearmind Medicine's Common Equity stood at -$1.1 million in 2022, then surged by 186.53% to $983472.0 in 2023, then jumped by 215.98% to $3.1 million in 2024, then tumbled by 61.62% to $1.2 million in 2025, then jumped by 863.51% to $11.5 million in 2026.
- Business Quant data shows CMND's Common Equity at $11.5 million in Q2 2026, $8.2 million in Q1 2026, and $1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | 11.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 11.49 Mn |
| Jan 31, 2026 | 8.24 Mn |
| Oct 31, 2025 | 1.19 Mn |
| Jul 31, 2025 | 1.07 Mn |
| Apr 30, 2025 | 2.30 Mn |
| Jan 31, 2025 | 2.85 Mn |
| Oct 31, 2024 | 3.11 Mn |
| Jul 31, 2024 | 3.47 Mn |
| Apr 30, 2024 | 4.65 Mn |
| Jan 31, 2024 | 5.04 Mn |
| Oct 31, 2023 | 983,472.00 |
| Jul 31, 2023 | 2.78 Mn |
| Apr 30, 2023 | 3.27 Mn |
| Jan 31, 2023 | 3.84 Mn |
| Oct 31, 2022 | -1.14 Mn |
| Jan 31, 2022 | 2.42 Mn |
| Oct 31, 2021 | 3.82 Mn |